Actively Recruiting
Phase 2 Study of Azacitidine Combined With R-CHOP for Treating TP53-Mutated Newly Diagnosed Diffuse Large B-Cell Lymphoma
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
52
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and side effects of combining Azacitidine with R-CHOP chemotherapy in treating patients with newly diagnosed TP53-mutated Diffuse Large B-cell Lymphoma DLBCL. This Phase 2, open-label study focuses on important outcomes like complete remission, overall survival, and progression-free survival. Participants will receive a specified dose of Azacitidine subcutaneously from day 1 to day 5, along with R-CHOP components including Rituximab, Cyclophosphamide, Epirubicin or Liposomal Adriamycin, Vincristine, and Prednisone administered on scheduled days. The study involves a single treatment arm using this combination, monitored over a period of up to 36 months. During the study, participants will undergo regular assessments to measure response rates such as complete and partial remission, overall response, and progression-free survival. Safety and side effects will be closely monitored throughout. The study aims to follow participants for up to three years to understand long-term outcomes and treatment effects.
CONDITIONS
Brief Title
AZA Combined With RCHOP in P53-mutated DLBCL.
Research Team
B
Bing Xu
Z
Zhifeng Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
